Regeneron Pharmaceuticals Inc. buy Morgan Stanley
Summary
This prediction is currently active. The prediction currently has a performance of 24.64%. This prediction currently runs until 11.10.24. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -1.431% | -1.431% |
iShares Core DAX® | -0.612% | 0.567% |
iShares Nasdaq 100 | -3.018% | -3.205% |
iShares Nikkei 225® | -2.647% | 0.330% |
iShares S&P 500 | -1.932% | -1.126% |
Comments by Morgan_Stanley for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
11.07.24
11.07.25
24.07.24
Regeneron Pharmaceuticals Inc.
18.03.24
18.03.25
24.07.24
Regeneron Pharmaceuticals Inc.
03.11.23
03.11.24
24.07.24
Regeneron Pharmaceuticals Inc.
04.08.23
04.08.24
24.07.24